Tg Therapeutics (TGTX) Net Margin (2017 - 2026)

Tg Therapeutics' Net Margin history runs 10 years deep, the most recent figure standing at 9.64% for Q1 2026.

• In Q1 2026, Net Margin rose 545.0% year-over-year to 9.64%; the TTM figure through Mar 2026 stood at 66.01% (up 5380.0% YoY), while the FY2025 annual figure was 72.62%, up 6306.0% from the prior year.
• Net Margin for Q1 2026 stood at 9.64%, down from 12.17% in the prior quarter.
• The five-year high for Net Margin was 241.73% in Q3 2025, with the low at 94568.75% in Q4 2022.
• The 5-year median for Net Margin is 4.19% (2025), against an average of 8928.61%.
• The sharpest annual moves came in 2022 and 2023: Net Margin slumped 9043747 bps in 2022, then soared 9453844 bps in 2023.
• Tg Therapeutics' Net Margin stood at 94568.75% in 2022, then soared by 100 bps to 30.31% in 2023, then surged by 196 bps to 29.01% in 2024, then tumbled by 58 bps to 12.17% in 2025, then retreated by 21 bps to 9.64% in 2026.
• Business Quant data shows TGTX's Net Margin at 9.64% in Q1 2026, 12.17% in Q4 2025, and 241.73% in Q3 2025.